Abstract
The LKEKK peptide (Np5) corresponding to the 16–20 sequence of thymosin-α1 (TM-α1) and to the 131–135 sequence of interferon-α2 (IFN-α2) and its [3H]Np5 analog were synthesized. [3H]Np5 was found to bond to human keratinocytes with high affinity and specificity (Kd 2.6 nM). Np5 dose-dependently decreased the inerleukin-17A-induced production of inflammatory cytokines (TNF-α, IL-6, and IL-1α) by keratinocytes in a concentration range from 50 to 1000 nM and increased a production of the anti-inflammatory IL-10 cytokine in vitro. The peptide effect was shown to be mediated through an activation of soluble guanylate cyclase.
Similar content being viewed by others
REFERENCES
Breitkreutz, D., Mirancea, N., and Nischt, R., Histochem. Cell. Biol., 2009, vol. 132, pp. 1–10. https://doi.org/10.1007/s00418-009-0586
Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., and Morel, F., J. Immunol., 2010, vol. 184, pp. 5263–5270. https://doi.org/10.4049/jimmunol.0902464
Robeony, H., Petit-Paris, I., Garnier, J., Barrault, C., Pedretti, N., Guilloteau, K., Jegou, J-F., Guillet, G., Huguier, V., Lecron, J-C., Bernard, F-X., and Morel, F., PLoS One, 2014, vol. 9, e101937. https://doi.org/10.1371/journal.pone.0101937
Navolotskaya, E.V., Zinchenko, D.V., Zolotarev, Y.A., Kolobov, A.A., and Lipkin, V.M., Biochemistry (Moscow), vol. 81, pp. 871–875. https://doi.org/10.1134/S0006297916080071
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V., Lipkin, V.M., and Zav’yalov, V.P., Int. Immunopharmacol., 2017, vol. 50, pp. 279–282. https://doi.org/10.1016/j.intimp.2017.07.011
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V., Vladimirov, V.I., Zolotarev, Y.A., and Kolobov, A.A., Russ. J. Bioorg. Chem., 2016, vol. 42, pp. 479–483. https://doi.org/10.1134/S1068162016050137
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V., Vladimirov, V.I., and Zolotarev, Y.A., Russ. J. Bioorg. Chem., 2017, vol. 43, pp. 673–677. https://doi.org/10.1134/S1068162017060115
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V., Vladimirov, V.I., Zolotarev, Y.A., and Lipkin, V.M., Russ. J. Bioorg. Chem., 2018, vol. 44, pp. 403–407. https://doi.org/10.1134/S1068162018030123
Navolotskaya, E.V., Sadovnikov, V.B., Lipkin, V.M., and Zav’yalov, V.P., Toxicol. In Vitro, 2018, vol. 47, pp. 269–273. https://doi.org/10.1016/j.tiv.2017.12.010
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V., Vladimirov, V.I., Zolotarev, Y.A., Lipkin, V.M., and Murashev, A.N., Russ. J. Bioorg. Chem., 2019, vol. 45, pp. 122–128. https://doi.org/10.1134/S1068162019020092
Cuatrecasas, P., Biochemistry, 1973, vol. 12, pp. 3558–3566.
Holmgren, J., Lonnroth, I., and Svennerholm, L., Infect. Immun., 1973, vol. 8, pp. 208–214.
Navolotskayaa, E.V., Sadovnikov, V.B., Lipkin, V.M., and Zav’yalov, V.P., J. Clin. Exp. Immunol., 2019, vol. 4, pp. 1–6. https://doi.org/10.33140/JCEI.04.04.03
Feelisch, M., Kotsonis, P., Siebe, J., Clement, B., and Schmidt, H.H., Mol. Pharmacol., 1999, vol. 56, pp. 243–253. https://doi.org/10.1124/mol.56.2.243
Chorachoo, J., Lambert, S., Furnholm, T., Roberts, L., Reingold, L., Auepemkiate, S., Voravuthikunchai, S.P., and Johnston, A., PLoS One, 2018, vol. 13. e0205340. https://doi.org/10.1371/journal.pone.0205340
Zolotarev, Y.A., Dadayan, A.K., Bocharov, E.V., Borisov, Y.A., Vaskovsky, B.V., Dorokhova, E.M., and Myasoedov, N.F., Amino Acids, 2003, vol. 24, pp. 325–333. https://doi.org/10.1007/s00726-002-0404-7
Pennock, B.E., Anal. Biochem., 1973, vol. 56, pp. 306–309.
Cheng, Y.C. and Prusoff, W., Biochem. Pharmacol., 1973, vol. 22, pp. 3099–3108.
Schultz, G. and Buhme, E., Methods of Enzymatic Analysis, Weinheim, Germany: Verlag Chemie, 1984, pp. 379–389.
Southam, E., Curr. Protoc. Toxicol., 2001, vol. 10, p. 10.5. https://doi.org/10.1002/0471140856.tx1005s04
Lowry, O.H., Rosebbrough, N.J., Farr, O.L., and Randal, R.J., J. Biol. Chem., 1951, vol. 193, pp. 265–275.
Funding
This study was supported by the Program for Basic Research of the Presidium of the Russian Academy of Sciences (Molecular and Cellular Biology), project no. III-12 (a project director was the corresponding member of the Russian Academy of Sciences, V.M. Lipkin).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
This article does not contain any studies involving human participants performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Conflict of Interests
The authors declare that they have no conflicts of interest.
Additional information
Translated by L. Onoprienko
Abbreviations: CT-B, B-subunit of choleraic toxin; cGMP, cyclic guanosine-3',5'-monophosphate; DSS, dextran sodium sulfate; IFN, interferon; iNOS, inducible NO-synthase; LPS, lipopolysaccharide; ODQ, (1H-[1,2,4]oxadiazolo[4,3-α]quinoxalyn-1-one; pGC, membrane-bond guanylate cyclase; sGC, soluble guanylate cyclase; TM-α1, thymosin-α1.
Corresponding author: phone: +7 (496) 773-66-68; fax: +7 (496) 733-05-27.
Rights and permissions
About this article
Cite this article
Navolotskaya, E.V., Sadovnikov, V.B., Zinchenko, D.V. et al. Effect of the LKEKK Peptide on Human Keratinocytes. Russ J Bioorg Chem 46, 1038–1043 (2020). https://doi.org/10.1134/S1068162020060229
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162020060229